Key Highlights

  • Shares were down 15.41% to USD 1.57 in regular trading on November 3, 2026.
  • Nasdaq notified the company on October 28, 2026 that it no longer meets the USD 50 million Market Value of listed securities requirement.
  • A second notice cites the USD 15 million minimum for market value of publicly held shares.
  • The company has until April 26, 2027 to regain compliance on both rules.
  • A 10-for-1 share consolidation took effect alongside the end of the ADR program in October 2026.

What Moved PomDoctor Today (down USD 0.2860, 15.41%)

PomDoctor (NASDAQ:POM) was down 15.41% to USD 1.57 in regular trading on November 3, 2026, versus a close of about USD 1.86 on Monday, November 2 (calculated from the screen move). Volume was about 84.62K shares, and the screen shows a Market Capitalisation of about USD 4.99 million.

The move follows a company press release dated November 2, 2026, announcing that it had received two continued listing notifications from the Nasdaq Listing Qualifications Department. Such notices put a shortfall on the public record, and small caps often weaken as holders reassess listing risk.

The Two Nasdaq Notices in Detail

According to the release, the letters are dated October 28, 2026 and followed a review of the 30 consecutive Business days from September 16 through October 27, 2026. The first notice says the company no longer meets the minimum market value of listed securities of USD 50 million required under Nasdaq Listing Rule 5450(b)(2)(A).

The second says it falls short of the USD 15 million minimum market value of publicly held shares. Each deficiency carries a 180-day cure period ending April 26, 2027. To regain compliance, the relevant market value must close at or above the threshold for at least 10 consecutive business days. The notices do not immediately affect trading.

Business Background and Recent Corporate Actions

PomDoctor is a Cayman Islands company based in Guangzhou, China. It describes itself as a digital healthcare company focused on AI-enabled and predictive healthcare, using physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world data.

In October 2026 the company ended its American depositary receipt program and moved to trade Class A ordinary shares directly on Nasdaq, expected before the open on October 21, 2026, according to a company press release. Each 10 ADSs were to convert into 3 post-consolidation Class A shares, and every 10 ordinary shares of each class became 1 share. Before the consolidation, 27,802,964 ordinary shares were outstanding as of September 2, 2026. Class B shares carry 20 votes each against 1 vote for Class A.

Risks and Balance Sheet Considerations

This report could not identify audited figures for revenue, losses, cash or Debt from the sources reviewed, so none are cited here. The notices themselves point to a small market value relative to Nasdaq thresholds. The company said only that it will monitor both measures and evaluate its options, without a specific plan.

As a penny stock, the shares carry high volatility, thin Liquidity and potential dilution risk, particularly if capital is raised to address the deficiencies. If compliance is not regained by April 26, 2027, the company would receive written notice of delisting, which it could appeal to a hearings panel.

What to Watch Next

Key items are the daily market value of listed securities against USD 50 million, further regulatory filings, and any capital actions. Trading in a stock this small can change quickly, so price levels may differ sharply from session to session.